Bragar Eagel & Squire, P.C. Announces that it Is Investigating the Boards of Directors of Home BancShares, Valley National, Kraton Corporation, and Acceleron Pharma on behalf of Stockholders and Encourages Investors to Contact the Firm

 

Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of Home BancShares, Inc. (NASDAQ: HOMB), Valley National Bancorp (NASDAQ: VLY), Kraton Corporation (NYSE: KRA), and Acceleron Pharma, Inc. (NASDAQ: XLRN).  Additional information about each potential action can be found at the link provided.

 

  Home Bancshares, Inc. (NASDAQ: HOMB)  

 

On September 28, 2021, Home BancShares announced that it had entered into an agreement to acquire Happy Bancshares in a transaction valued at approximately $919 million. Pursuant to the merger agreement, Happy Bancshares stockholders will receive 2.17 shares of Home BancShares common stock for each share of Happy Bancshares common stock owned. The deal is scheduled to close in the first quarter of 2022.

 

Bragar Eagel & Squire is concerned that Home BancShares' board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Home BancShares' stockholders.

 

To learn more about the Home BancShares investigation go to: https://bespc.com/cases/homb .

 

  Valley National Bancorp (NASDAQ: VLY)  

 

On September 23, 2021, Valley National announced that it had entered into an agreement to acquire Leumi in a stock-plus-cash transaction. Pursuant to the merger agreement, Leumi stockholders will receive $5.08 in cash and 3.8025 shares of Valley National common stock for each share of Leumi common stock owned. The deal is scheduled to close in the first quarter of 2022.

 

Bragar Eagel & Squire is concerned that Valley National's board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Valley National's stockholders.

 

To learn more about the Valley National investigation go to: https://bespc.com/cases/vly .

 

  Kraton Corporation (NYSE: KRA)  

 

Buyer: DL Chemical Co., Ltd.

 

On September 27, 2021, Kraton announced that it had entered into an agreement to be acquired by DL Chemical in a transaction valued at approximately $2.5 billion. Pursuant to the merger agreement, Kraton stockholders will receive $46.50 in cash for each share of Kraton common stock owned. The deal is scheduled to close in the first half of 2022.

 

Bragar Eagel & Squire is concerned that Kraton's board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Kraton's stockholders.

 

To learn more about the Kraton investigation go to: https://bespc.com/cases/kra .

 

  Acceleron Pharma, Inc. (NASDAQ: XLRN)  

 

Buyer: Merck & Co., Inc. (NYSE: MRK)

 

On September 30, 2021, Acceleron announced that it had entered into an agreement to be acquired by Merck in a transaction valued at approximately $11.5 billion. Pursuant to the merger agreement, Acceleron stockholders will receive $180 in cash for each share of Acceleron common stock owned. The deal is scheduled to close in the fourth quarter of 2021.

 

Bragar Eagel & Squire is concerned that Acceleron's board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Acceleron's stockholders.

 

To learn more about the Acceleron investigation go to: https://bespc.com/cases/xlrn .

 

  About Bragar Eagel & Squire, P.C.:  
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com . Attorney advertising. Prior results do not guarantee similar outcomes.

 

  Contact Information:  
Bragar Eagel & Squire, P.C.
Melissa A. Fortunato, Esq.
Alexandra Raymond, Esq.
  investigations@bespc.com   
  www.bespc.com   

 

 

 


  

 

 

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
Various blister packs with pills and capsules in different colors and shapes.

Trump Signs Sweeping Order to Slash Drug Prices, Pressure Pharma Giants

US President Donald Trump has signed a sweeping executive order aimed at dramatically reducing prices for prescription drugs, vowing to end “foreign free-riding” on American pharmaceutical innovation.

The order directs federal agencies to pressure both drug manufacturers and wealthy foreign countries to bring their prices in line with those paid in the US, or face aggressive trade and regulatory actions.

“In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism abroad with skyrocketing prices at home,” Trump states in the order.

Keep reading...Show less
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2025

The global pharmaceutical market reached a total value of US$1.38 trillion in 2024, according to Research and Markets, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Keep reading...Show less
Invion Limited

Invion Limited

Keep reading...Show less
Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Top 5 Small-cap Pharma Stocks in 2025

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval.

However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2024, 50 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 55 such approvals in 2023. Last year's FDA approvals include Eli Lilly and Company's (NYSE:LLY) Alzheimer's disease treatment Kisunla.

Big pharma largely steals the show, but some small- and mid-cap NASDAQ pharma stocks have also made gains.

Keep reading...Show less
Cardiol Therapeutics (TSX:CRDL)

Cardiol Therapeutics Announces Year-End 2024 Update on Operations

Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial

Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patients
with acute myocarditis, with topline data expected in Q2 2025

Keep reading...Show less

Latest Press Releases

Related News

×